The Impact of non-COVID-19 Infections to COVID-19 Disease in Hematological and Solid Organ Malignancies

INTRODUCTION: The aim of this study is to evaluate the clinical differences of COVID-19 infection in hematological and solid organ malignancy patients.
METHODS: In the study, patients who have followed up in the Necmettin Erbakan University Meram Medical Faculty Clinic of COVID-19 with a diagnosis of malignancy between 01 September 2020 and 01 January 2021 were compared in terms of epidemiological and clinical characteristics.
RESULTS: The study included 134 patients. Hospitalization day, intensive care need, convalescent plasma need, sedimentation and ferritin levels of patients diagnosed with hematological malignancies were significantly higher (p: 0.001, 0.008, 0.001, 0.001, <0.001 respectively), and the neutrophil, lymphocyte, platelet, and neutrophil-lymphocyte ratio was found to be low, according to the findings of the study. The cure rate of COVID infection was significantly lower with additionally infection in hematological malignancies (OR: 3.1, 95%; CI: 1.4-6.9; p: 0.004). In multivariate analysis, it was determined that an presence of non-COVID-19 infection increased the risk of death 2.8 times (95% CI; 1.3-6.5, p: 0.010).
DISCUSSION AND CONCLUSION: Patients with hematological malignancy have experienced a more severe clinical course of COVID-19 and higher mortality than those with solid tumors. The use of a model in the COVID-19 pandemic that summarizes these non-COVID-19 infections, hematological parameters, age, and comorbidities can help in the method of malignant patients with high mortality risk.

Hematolojik ve Solid Organ Malignitelerinde COVID-19 Dýþýndaki Enfeksiyonlarýn COVID-19 Hastalýðýna Etkisi

GÝRÝÞ ve AMAÇ: Çalýþmanýn amacý, hematolojik ve solid organ maligniteli hastalarda COVID-19 enfeksiyonundaki klinik farklarýn deðerlendirilmesidir.
YÖNTEM ve GEREÇLER: Çalýþmada 01.09.2020-01.01.2021tarihleri arasýnda Necmettin Erbakan Üniversitesi Meram Týp Fakültesi COVID-19 kliniðinde yatarak takip edilen malignite tanýlý hastalar epidemiyolojik ve klinik özellikleri açýsýndan karþýlaþtýrýldý
BULGULAR: Çalýþmaya 134 dahil edildi. Hematolojik maligniteli hastalarda hastanede yatýþ günü, yoðun bakým ihtiyacý, konvelesan plazma ihtiyacý, sedimentasyon ve ferritin düzeyleri daha yüksek (sýrasýyla; p: 0.001, 0.008, 0.001, 0.001, <0.001); nötrofil, lenfosit, trombosit ve nötrofil/lenfosit oraný daha düþük bulundu. COVID-19 enfeksiyonundan iyileþme oraný, ilave enfeksiyonun olduðu hematolojik maligniteli hastalarda, daha düþüktü (OR: 3.1, 95%; CI: 1.4-6.9; p: 0.004). Çok deðiþkenli analizde, COVID-19 dýþýnda bir enfeksiyon varlýðýnýn ölüm riskini 2,8 kat arttýrdýðý tespit edildi (%95 GA; 1.3-6.5, p: 0.010).
TARTIÞMA ve SONUÇ: COVID-19 enfeksiyonu hematolojik maligniteli hastalarda solid organ maligniteli hastalara göre daha þiddetli seyretmektedir. COVID-19 pandemisinde COVID-19 dýþý enfeksiyonlar, hematolojik parametreler, yaþ ve ko-morbiditeden oluþan bir modelin kullanýlmasý, yüksek mortalite riski olan malign hastalarýn yönetiminde yardýmcý olabilir.